Development of antibody-directed therapies: quo vadis?

Utilize este identificador para referenciar este registo: http://hdl.handle.net/10451/50253

Título:	Development of antibody-directed therapies: quo vadis?
Autor:	Rodrigues, Tiago Bernardes, Gonçalo J. L.
Palavras-chave:	Anti-tumor agents Antibody-drug conjugates Bioconjugation Drug delivery Linkers
Data:	2018
Editora:	John Wiley & Sons, Inc.
Citação:	Angew Chem Int Ed Engl. 2018 Feb 19;57(8):2032-2034
Resumo:	Less is more: The efficacy of antibody-drug conjugates (ADCs) for cancer therapy is traditionally associated with cleavable linkers for payload release. Evidence now suggests that simpler constructs without cleavable moieties can afford more stable and effective ADCs.
Descrição:	© 2018 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Peer review:	yes
URI:	http://hdl.handle.net/10451/50253
DOI:	10.1002/anie.201712185
ISSN:	1433-7851
Versão do Editor:	https://onlinelibrary.wiley.com/journal/15213773?tabActivePane=undefined
Aparece nas colecções:	IMM - Artigos em Revistas Internacionais FM - Artigos em Revistas Internacionais

Ficheiros deste registo:

Ficheiro	Descrição	Tamanho	Formato
Development_antibody.pdf		631,65 kB	Adobe PDF	Ver/Abrir